Pm. Bokesch et al., Neuroprotective, anesthetic, and cardiovascular effects of the NMDA antagonist, CNS 5161A, in isoflurane-anesthetized lambs, ANESTHESIOL, 93(1), 2000, pp. 202-208
Citations number
37
Categorie Soggetti
Aneshtesia & Intensive Care","Medical Research Diagnosis & Treatment
Background: N-methyl-o-aspartate (NMDA) receptor antagonists are neuroprote
ctive in animal models of cerebral ischemia, but adverse cardiovascular and
neurobehavioral effects have precluded their clinical use. The authors pre
sent the neuroprotective, anesthetic, and cardiovascular effects of a novel
NMDA antagonist, CNS 5161A.
Methods: Lambs, 4.0-6.5 kg, were anesthetized with isoflurane, intubated an
d ventilated and had thermodilution catheters placed in the pulmonary arter
y and 20-g catheters placed in the femoral artery. The minimum alveolar con
centration (MAC) of isoflurane was determined using the "bracketing techniq
ue." CNS 5161A was given as a bolus and then as an infusion at three doses.
Cardiovascular measurements were determined every 15 min. Other lambs (n =
25) were subjected to cardiopulmonary bypass (CPB) with hypothermic circul
atory arrest (HCA) for 120 min Eighteen received CNS 5161A, and seven recei
ved saline vehicle. One hour after CPB, brains were perfusion-fixed and rem
oved for in situ hybridization and immunohistochemistry analysis in half of
the animals. The other half survived 48 h before their brains were examine
d for neuronal degeneration.
Results: Isoflurane at MAC significantly decreased blood pressure, heart ra
te, cardiac output, and systemic vascular resistance by 30-48% (n = 16; P <
0.05). CNS 5161A (n = 12) had no significant cardiovascular effects. All c
oncentrations of CNS 5161A caused a significant reduction (21-29%) of the M
AC of isoflurane (n = 12; P < 0.05). CNS 5161A, at serum concentrations gre
ater than 25 ng/ml, completely inhibited c-fos mRNA and c-FOS protein expre
ssion in hippocampal neurons after 120 min of HCA, attenuated neuronal dege
neration, and improved functional outcome by 47% (P < 0.05).
Conclusions: CNS 5161A at neuroprotective concentrations before CPB-HCA sig
nificantly; reduces the MAC of isoflurane without cardiovascular effects.